Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection
- PMID:15983286
- DOI: 10.1001/archinte.165.12.1375
Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection
Abstract
Background: Infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species (ESBL-EK) have increased markedly in recent years. Risk factors for mortality among ESBL-EK infections have not been studied.
Methods: This retrospective cohort study was conducted in a 625-bed tertiary care medical center and a 344-bed urban community hospital to determine whether inadequate initial antimicrobial therapy (IIAT) (>48 hours between the time a culture was obtained and initiation of an agent to which the infecting organism was susceptible) is associated with mortality in ESBL-EK infections. All hospitalized patients with an ESBL-EK infection between June 1, 1997, and December 31, 2002, were eligible for inclusion. Subsequently, we conducted a nested case-control study to identify risk factors for IIAT.
Results: Of 187 subjects, 32 (17.1%) died while in the hospital. Clinical site of infection was a significant effect modifier in the association between IIAT and mortality. The presence of IIAT was an independent risk factor for mortality, but only for nonurinary ESBL-EK infections (adjusted odds ratio [95% confidence interval], 10.04 [1.90-52.96]). Independent risk factors for IIAT were (1) infection with a multidrug-resistant ESBL-EK (ie, resistant to sulfamethoxazole-trimethoprim, aminoglycosides, and quinolones) (14.58 [1.91-111.36]) and (2) health care-acquired ESBL-EK infection (4.32 [1.49-12.54]).
Conclusions: Inadequate initial antimicrobial therapy is an independent risk factor for mortality in ESBL-EK infections, but only among nonurinary infections. Multidrug resistance was a strong risk factor for IIAT.
Similar articles
- Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Fishman NO, Bilker WB, Mao X, Lautenbach E.Hyle EP, et al.Clin Infect Dis. 2005 May 1;40(9):1317-24. doi: 10.1086/429239. Epub 2005 Mar 30.Clin Infect Dis. 2005.PMID:15825035
- Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.Zaoutis TE, Goyal M, Chu JH, Coffin SE, Bell LM, Nachamkin I, McGowan KL, Bilker WB, Lautenbach E.Zaoutis TE, et al.Pediatrics. 2005 Apr;115(4):942-9. doi: 10.1542/peds.2004-1289.Pediatrics. 2005.PMID:15805368
- Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW.Kang CI, et al.Antimicrob Agents Chemother. 2004 Dec;48(12):4574-81. doi: 10.1128/AAC.48.12.4574-4581.2004.Antimicrob Agents Chemother. 2004.PMID:15561828Free PMC article.
- Extended-spectrum beta-lactamase-producing bacterial infections in adult solid organ transplant recipients.Winters HA, Parbhoo RK, Schafer JJ, Goff DA.Winters HA, et al.Ann Pharmacother. 2011 Mar;45(3):309-16. doi: 10.1345/aph.1P661. Epub 2011 Mar 8.Ann Pharmacother. 2011.PMID:21386016Review.
- Extended-spectrum beta-lactamases and clinical outcomes: current data.Ramphal R, Ambrose PG.Ramphal R, et al.Clin Infect Dis. 2006 Apr 15;42 Suppl 4:S164-72. doi: 10.1086/500663.Clin Infect Dis. 2006.PMID:16544267Review.
Cited by
- Strategic measures for the control of surging antimicrobial resistance in Hong Kong and mainland of China.Cheng VC, Wong SC, Ho PL, Yuen KY.Cheng VC, et al.Emerg Microbes Infect. 2015 Feb;4(2):e8. doi: 10.1038/emi.2015.8. Epub 2015 Feb 11.Emerg Microbes Infect. 2015.PMID:26038766Free PMC article.Review.
- Machine learning model for predicting ciprofloxacin resistance and presence of ESBL in patients with UTI in the ED.Lee HG, Seo Y, Kim JH, Han SB, Im JH, Jung CY, Durey A.Lee HG, et al.Sci Rep. 2023 Feb 25;13(1):3282. doi: 10.1038/s41598-023-30290-y.Sci Rep. 2023.PMID:36841917Free PMC article.
- Tigecycline use in serious nosocomial infections: a drug use evaluation.Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C.Bassetti M, et al.BMC Infect Dis. 2010 Sep 29;10:287. doi: 10.1186/1471-2334-10-287.BMC Infect Dis. 2010.PMID:20920273Free PMC article.
- Cost and mortality prediction using polymerase chain reaction pathogen detection in sepsis: evidence from three observational trials.Lehmann LE, Herpichboehm B, Kost GJ, Kollef MH, Stüber F.Lehmann LE, et al.Crit Care. 2010;14(5):R186. doi: 10.1186/cc9294. Epub 2010 Oct 15.Crit Care. 2010.PMID:20950442Free PMC article.
- Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea.Lee Y, Lee DG, Lee SH, Yoo KH.Lee Y, et al.J Korean Med Sci. 2016 Nov;31(11):1808-1813. doi: 10.3346/jkms.2016.31.11.1808.J Korean Med Sci. 2016.PMID:27709861Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials